Synthesis and evaluation of (S)-4-(3-(2'-[11C]isopropylamino)-2-hydroxypropoxy) -2H-benzimidazol -2-one ((S)-[11C]CGP 12388) and (S)-4-(3-((1'-[18F]-fluoroisopropyl)amino)-2-hydroxypropoxy) -2H- benzimidazol-2-one ((S)-[18F]fluoro-CGP 12388) for visualization of beta-adrenoceptors with positron emission tomography

Journal of Medicinal Chemistry
Philip H ElsingaW Vaalburg


The beta-adrenoceptor antagonist (S)-[11C]CGP 12177 (4-(3-(tert-butylamino)-2-hydroxypropoxy)-2H-benzimidazol -2[11C]- one) is a generally accepted radioligand for cardiac and pulmonary PET studies. The synthesis of [11C]CGP 12177 is a laborious and often troublesome procedure. Therefore, (S)-CGP 12388 (4-(3-(isopropylamino)-2-hydroxypropoxy) -2H-benzimidazol-2-one), 5, the isopropyl analogue of CGP 12177, has been labeled with carbon-11 in the isopropyl group via a reductive alkylation by [11C]acetone (3) of the corresponding (S)-desisopropyl compound 2. The fluoro-substituted analogue of (S)-CGP 12388 was prepared by reacting 2 with [18F]fluoroacetone (4). (S)-[11C]CGP 12388 (5) was easily prepared via a one-pot procedure. The radiochemical yield of (S)-[11C]CGP 12388 (600-800 Ci/mmol, EOS) was 18% (EOB) with a total synthesis time of 35 min, whereas (S)-[18F]fluoro-CGP 12388 (6) (> 2000 Ci/mmol, EOS) was synthesized in 105 min with a radiochemical yield of 12% (EOB). Biodistribution studies in rats demonstrated specific binding to beta-adrenoceptors of (S)-[18F]fluoro-CGP 12388 and (S)-[11C]CGP 12388 in lung and heart. The lungs were clearly visualized with PET studies of rats. Total/nonspecific binding at 60 min postinjecti...Continue Reading


Dec 14, 2004·European Journal of Nuclear Medicine and Molecular Imaging·Richard M de JongPhilip H Elsinga
May 5, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Riikka LautamäkiFrank M Bengel
Oct 9, 2004·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Frank M Bengel, Markus Schwaiger
May 7, 1998·European Journal of Pharmacology·Aren van WaardeW Vaalburg
May 17, 2000·Pharmaceutica acta Helvetiae·Victor W PikeP G Camici
Nov 27, 2001·Bioorganic & Medicinal Chemistry Letters·Mark A AshwellJeffery Tillet
Jul 25, 2003·Bioorganic & Medicinal Chemistry·Klaus KopkaMichael Schäfers
May 9, 2000·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·T J VisserW Vaalburg
Apr 4, 2002·Nuclear Medicine and Biology·K NishijimaN Tamaki
Oct 1, 2003·Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T·Philip H ElsingaWillem Vaalburg
Sep 2, 2006·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·K Nishijima
Mar 10, 2006·Current Cardiology Reports·Takahiro Higuchi, Markus Schwaiger
Apr 21, 2004·Journal of Veterinary Pharmacology and Therapeutics·L R SomaP Habecker
Mar 28, 2007·Heart Failure Clinics·Takahiro Higuchi, Markus Schwaiger
Oct 27, 2007·Neurochemistry International·Aren van WaardePhilip H Elsinga
Dec 24, 2017·Journal of Labelled Compounds & Radiopharmaceuticals·Carlotta Taddei, Antony D Gee
May 2, 2001·The British Journal of Psychiatry : the Journal of Mental Science·L N YathamT J Ruth
Jun 3, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·William C Eckelman, Vasken Dilsizian

Related Concepts

Related Feeds


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.